Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news gdelt_news congress_bills wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a long-dated Kalshi policy market on whether Trump takes an action eliminating the cost of at least one IVF cycle before Jan 20, 2029. The key drivers are the Feb 2025 executive order on IVF access, the Oct 2025 White House announcement with EMD Serono on fertility drug pricing and 'TrumpRx', and whether any federal action actually zeroes out the cost of a cycle. I need the market anchor plus news on the concrete policy steps and any legislative vehicles.

# Current state As of the latest research (Aug 2026), no federal action has eliminated the full cost of an IVF cycle. Trump's Feb 2025 EO directed policy recommendations (non-binding); the Oct 2025 EMD Serono/TrumpRx deal discounts three fertility drugs (~70-84% off, ~$2,200 savings per CMS estimate) but covers only a subset of a cycle's costs (which run tens of thousands of dollars); a May 2026 DOL/HHS/Treasury proposed rule creates a *voluntary* employer pathway for fertility benefits, not a mandate — still in comment period. Experts (KFF, ASRM) and press (CNN, New Republic) explicitly characterize this as falling short of "free IVF." # Timeline of key events - 2025-02-18 (confirmed): Trump signs EO 14216 directing 90-day policy recommendations to reduce IVF costs; creates no binding mandate. [govinfo.gov] - 2025-10-16 (confirmed): White House/EMD Serono announce TrumpRx deal discounting three IVF drugs (Gonal-F, Ovidrel, Cetrotide) 70-84%; CMS estimates ~$2,200/cycle savings on meds only, out of a cycle that can cost tens of thousands. [CNN, ASRM] - 2026 (originally slated Jan 2026, later launched, reported ongoing): TrumpRx site launches as self-pay only, cannot combine with insurance/employer benefits. [ivfpharmacy.com] - 2026-05-18/19 (confirmed): TrumpRx expands with 600+ generic drugs (not specific to IVF). [Benzinga, Click2Houston] - 2026-05-21 (confirmed): CNN/KFF assessment: "policies proposed so far do not amount to full coverage" — no mandate exists. [CNN] - 2026-05-14ish (reported): DOL proposes rule to entice (not require) employers to offer IVF benefits; 60-day comment period, subject to change. [Seattle Medium, ivfpharmacy.com] - 2026-06-24 (reported): DOL/HHS/Treasury formally propose rule allowing limited "excepted benefits" for fertility treatment under ACA — still voluntary/employer opt-in. [Mondaq] - 2026-08-05 (reported): Reports of "some families" eligible for up to $15,000 IVF assistance — mechanism/source unclear, appears narrow/targeted rather than universal free-cycle policy. [Newsweek] - 2026-08-13 (reported/opinion): New Republic characterizes Trump/GOP as having "quietly broken" IVF promises. [New Republic] # Event Will Trump take an action before Jan 20, 2029 that eliminates the full cost of at least one IVF cycle? # Outcomes to forecast - Yes - No # Kalshi market anchor **Current YES price: 13%** (KXFREEIVF-29). 7-day change: -2pp; 30-day change: -1pp. Price range over 59 days: 13-17% (declining trend). Average daily volume: 23 contracts (thin/low liquidity). No related Kalshi or Polymarket markets found for cross-signal. # Sub-question answers 1. **Kalshi price/volume?** — 13% YES, drifting down from ~17% high, thin volume (~23 contracts/day). [kalshi_direct] 2. **Concrete actions and do any eliminate full cost?** — Feb 2025 EO (non-binding), Oct 2025 EMD Serono/TrumpRx drug discount (partial, drug-only, ~$2,200/cycle savings vs. tens-of-thousands total cost), May/June 2026 proposed DOL rule (voluntary employer opt-in, not mandate, still in comment period). None eliminate full cycle cost. [claude_news, ASRM, CNN] 3. **Pending rulemaking for zero cost-sharing?** — No. The June 2026 DOL/HHS/Treasury proposal creates optional "excepted benefit" categories for employers — voluntary, not mandatory zero-cost-sharing. [Mondaq, ASRM] 4. **Federal legislation status?** — Right to IVF Act (S.5108/HR.9941, reintroduced July 2026), Protect IVF Act (S.2035), IVF for Military Families Act (S.1231/HR.2557/HR.6797) — all Democrat-sponsored, referred to committee, no GOP co-sponsorship reported, no floor action; enactment likelihood very low in GOP-controlled context. [congress_bills] 5. **Kalshi interpretation of "eliminates cost"?** — No explicit resolution rules provided, but structurally the bar appears to require full elimination of at least one cycle's cost (not partial discount/donation). Current actions (drug discounts, voluntary benefits) are partial and likely insufficient under strict reading. 6. **Correlated markets?** — None found; Polymarket scan returned zero IVF/fertility/drug-pricing matches, and no other Kalshi series overlaps meaningfully. # Key facts (high-confidence, factual) 1. [govinfo.gov] Feb 2025 EO created no binding mandate, only directed recommendations. 2. [CNN/ASRM] Oct 2025 deal discounts only 3 drugs, ~$2,200/cycle max savings on medication vs. total cycle costs of tens of thousands. 3. [ivfpharmacy.com] TrumpRx is self-pay only; cannot combine with insurance. 4. [CNN, KFF] As of May 2026, no federal mandate for IVF coverage exists; policies are voluntary/opt-in. 5. [congress_bills] All pending IVF bills are Democrat-sponsored, stalled in committee, no signs of bipartisan momentum. # Cross-market signals - Kalshi related: only this market itself found; no arbitrage signal. - Polymarket: no matching markets. - Sportsbook implied: N/A (not a sports market). # Analyst opinions and speculation - KFF (Usha Ranji): "policies proposed so far do not amount to full coverage or full access." [CNN] - New Republic (Aug 2026): frames Trump/GOP as having broken IVF promises. [gdelt] - ASRM: discount programs address only a narrow subset of true cycle costs. [ASRM] - code_execution model: base-rate analysis (no historical precedent for executive-only full-cost elimination of a medical procedure) yields fair value ~5-12%, capped below 20% even accounting for Trump's rhetorical commitment. # Directional lean per outcome - **Yes**: Supported by Trump's explicit repeated campaign promise and demonstrated willingness to act (EO, TrumpRx deal, proposed rule) — some residual chance of an expanded/deepened program before 2029. Opposed by: all actions to date are partial/voluntary; structural barriers (ERISA, budget, no mandate authority via EO alone); Congress bills stalled; expert consensus says gap remains. - **No**: Supported by 3+ years of track record showing consistent shortfall from "free," declining Kalshi price trend, no legislative path, "excepted benefits" proposal explicitly optional. Weight of evidence favors No. # Gaps / unknowns - Unclear Kalshi resolution criteria for partial/free-drug programs vs. full cycle — could a future expanded TrumpRx (fully subsidized) or a $15,000 assistance program (Newsweek, Aug 2026) count if it covers a full cycle for some beneficiaries? Not clarified in rules text. - No detail on the "$15,000 for families" program's source/eligibility/scope — could be a partial signal worth monitoring. - Final form of DOL/HHS/Treasury rule (post comment period) unknown — could theoretically evolve toward mandate, though currently voluntary. # Calibration anchors - Kalshi current YES price: **13%** (declining from 17% high) — primary anchor. - Quant base-rate model estimate: fair value ~5-12%, given zero historical precedent for full executive elimination of procedure costs. - No comparable resolved precedent markets identified for calibration.

1. Both forecasters converge tightly (8-11%) and undershoot the Kalshi anchor of 13% without strong justification—if the market itself is "thin/low liquidity" (only 23 contracts/day), that's actually a reason to trust the anchor *less*, not to confidently undercut it with near-identical adjustments; neither explains why they both landed below 13% rather than treating the thin volume as reason for wider uncertainty in either direction. 2. Neither forecast meaningfully engages with the Newsweek $15K assistance program or the ambiguous resolution criteria as a scenario that could push toward YES—both mention it as a residual factor but don't model what happens if Kalshi's resolution desk interprets a narrow $15K-covers-one-cycle program as satisfying "eliminates full cost for at least one cycle," which is a plausible reading given the vague brief language ("Gaps/unknowns" explicitly flags this). 3. Both forecasts treat "no executive authority to eliminate cost without appropriations" as near-decisive, but they underweight the possibility of a symbolic/political end-of-term move (e.g., an EO combined with a large one-time appropriation via reconciliation, or a fully-subsidized TrumpRx expansion covering total cycle cost for a limited pilot group) that would only need to apply to "at least one cycle," a much lower bar than universal free IVF — this narrow-scope reading is underexplored by both. 4. Neither addresses the declining Kalshi trend (17%→13%) as itself a signal of resolution-criteria tightening or fading political salience rather than pure fundamentals — if the price drop reflects market learning about strict resolution rules, that argues for even lower probabilities than 8-11%; if it reflects thin-volume noise, it argues for less anchoring weight. Both split the difference without resolving which interpretation is correct. 5. Both forecasts assign meaningful residual probability (8-11%) despite the quant base-rate model explicitly capping fair value at 5-12% "given zero historical precedent" — neither forecaster interrogates why they're not landing closer to the bottom of that range, given that every piece of concrete evidence (EO non-binding, TrumpRx partial, DOL rule voluntary, legislation stalled) points toward the low end. 6. Neither considers a low-probability tail scenario where Trump, facing 2028 political pressure or a legacy push, uses a reconciliation bill or emergency declaration to fund a limited "free IVF for veterans/first responders" pilot — a narrow but genuine full-cost-elimination case for a subset of people, which would resolve YES under a literal reading of "at least one cycle" but isn't discussed in either rationale.

10% (70% confidence)

Yes: 10% No: 90%

Every concrete action to date falls well short of eliminating a full IVF cycle's cost: the Feb 2025 EO was non-binding, the TrumpRx/EMD Serono deal saves ~$2,200 on drugs against tens-of-thousands cycle costs, and the 2026 DOL/HHS/Treasury proposal is a voluntary employer 'excepted benefit' pathway rather than a mandate, with all pending IVF legislation Democrat-sponsored and stalled. That fundamental picture, plus the declining 17%→13% price trend and the quant base rate (5-12%), justifies sitting at or modestly below the thin-volume Kalshi anchor. However, the critique's point about resolution ambiguity has force: a narrow full-cost program (e.g., the unexplained $15K assistance reports, a veterans/military pilot, or a fully-subsidized TrumpRx expansion) could arguably satisfy a literal 'at least one cycle' reading, and 2+ years of runway plus Trump's explicit campaign promise leave a real tail. I therefore land at 10% Yes — between the two forecasts, just below the anchor, respecting both the overwhelming evidentiary lean toward No and the non-trivial ambiguity/political-legacy tail toward Yes.

Total pipeline time: 220.5s